Shanghai Haohai Biological Technology, which makes absorbable biomedical medical devices, will raise as much as $305 million in a Hong Kong IPO; WuXi PharmaTech invested $15 million in DNAnexus of Boston and will place its genomic services on the DNAnexus cloud-based platform; Kunming Biomed of China signed up BTS Research of San Diego to import and distribute KBI’s non-human primates in the western United States; Aliyun, an Alibaba subsidiary, will work with two other China companies to build China's first cloud hospital; the ChinaBio® Partnering Forum 2015 brought a record 858 internationally-focused life science executives and investors to Shanghai on April 15-16; the CBPF discussed innovation in drug development, though individual companies seemed to have different ideas of what the concept means; a Plenary Panel at the CBPF concluded that economics force biologic companies to develop both innovative biotech drugs and biosimilars; Uni-Bio Science Group of Hong Kong filed for China approval of Uni-PTH, the company's proprietary treatment for osteoporosis; and PPD, the US-based CRO, opened a central laboratory in Shanghai at the Shanghai Clinical Research Center.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
